. Author manuscript; available in PMC: 2014 Aug 1.

Published in final edited form as: Hematol Oncol Clin North Am. 2013 Jun 18;27(4):737–749. doi: 10.1016/j.hoc.2013.05.003

Table 1.

Overview of Targeted Strategies in Advanced Triple Negative Breast Cancer

Therapeutic Target	Phase of Study	References
Angiogenesis	Phase III	38
PARP inhibition	Phase I/II	39,40
EGFR inhibition	Phase II	41,37
Androgen Receptor signaling	Phase II	13
PI3K inhibition	Preclinical/Phase I	42
MEK inhibition	Preclinical	46, 47
CHK inhibition	Preclinical	43, 44
HDAC inhibition	Preclinical/Phase II	48, 49